Epcoritamab Plus R-mini-CVP in Frail, Elderly Patients With Newly Diagnosed DLBCL

Dr. Matthew Karr outlines the phase 2 trial design and patient population for epcoritamab plus R-mini-CVP in frail, elderly, newly diagnosed DLBCL.

Dr. Matthew Karr shares efficacy results from a trial of epcoritamab plus R-mini-CVP in elderly DLBCL, including an 86% complete response rate.

Dr. Matthew Karr reviews safety and tolerability data for epcoritamab plus R-mini-CVP, including full treatment completion in frail, elderly patients with DLBCL.

Dr. Matthew Karr and Dr. Shreyas Kalantri discuss what's next for chemo-free DLBCL regimens and open questions following the epcoritamab R-mini-CVP data.